SCHEMBL2395590

SCHEMBL2395590

NC(=O)C(O)c1ccccc1-c1cc(F)cc(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.42
TRPM8 Q7Z2W7 1/20 0.38
CHRM3 P20309 3/20 0.37
KCNA5 P22460 1/20 0.37
GRM2 Q14416 2/20 0.36
PDK2 Q15119 1/20 0.36
CTSA P10619 3/20 0.34
FGFR1 P11362 1/20 0.34
SRC P12931 1/20 0.34
FGFR2 P21802 1/20 0.34
FGFR4 P22455 1/20 0.34
FGFR3 P22607 1/20 0.34
MET P08581 1/20 0.34
SLC9A1 P19634 2/20 0.33
PTPRC P08575 1/20 0.33
SCN9A Q15858 1/20 0.33
GRM5 P41594 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2391614 0.90 APP (0.43) APPKCNA5PDK2CTSAFGFR1
SCHEMBL2393200 0.90 APP (0.43) APPKCNA5PDK2CTSAFGFR1
SCHEMBL2393198 0.90 APP (0.43) APPKCNA5PDK2CTSAFGFR1
SCHEMBL12202160 0.83 CTSA (0.38) TRPM8CTSAMETSLC9A1GRM5
SCHEMBL9890803 0.81 CHRM1 (0.46) CHRM3SLC9A1
SCHEMBL2393221 0.81 SLC9A1 (0.42) FGFR1FGFR3SLC9A1
SCHEMBL2391794 0.80 APP (0.50) APPCHRM3GRM2CTSASCN9A
SCHEMBL2393512 0.80 APP (0.47) APPCHRM3CTSASCN9A
SCHEMBL2395250 0.80 ALOX5AP (0.39) APPTRPM8CHRM3
SCHEMBL9890802 0.79 SLC6A4 (0.44) GRM2SLC9A1SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US claimed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP claimed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US claimed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
WO-2010055911-A1 BIPHENYLACETAMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 APP 2725/4885TRPM8 2090/4885CHRM3 298/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 APP 2725/4885TRPM8 2090/4885CHRM3 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.